SCHEMBL14419217

SCHEMBL14419217

CC(=O)CNc1c([N+](=O)[O-])c2nnnn2c2ncccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.34
ELANE P08246 2/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.34
KDM4E B2RXH2 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 5/20 0.33
ALDH1A1 P00352 3/20 0.33
CTSB P07858 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32
BRD4 O60885 1/20 0.32
HSP90AA1 P07900 1/20 0.32
CHRM1 P11229 1/20 0.32
DRD2 P14416 1/20 0.32
ALOX12 P18054 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
CHRM3 P20309 1/20 0.32
HTR2C P28335 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13914465 0.89 MAPT (0.37) LMNAELANEPTGDR2KDM4ESMN1; SMN2
SCHEMBL12701776 0.84 KDM4E (0.32) LMNAPTGDR2KDM4ESMN1; SMN2MAPT
SCHEMBL7025149 0.84 MAPT (0.38) LMNAKDM4ESMN1; SMN2MAPTALDH1A1
SCHEMBL14419219 0.80 ALDH1A1 (0.32) LMNAMAPTALDH1A1HTT
SCHEMBL3354370 0.77 S100A4 (0.42) LMNAELANEKDM4ESMN1; SMN2MAPT
SCHEMBL14419213 0.77 KMT2A (0.31) KDM4EALDH1A1KMT2AHTT
SCHEMBL4302874 0.75 ALDH1A1 (0.39) LMNAELANEKDM4ESMN1; SMN2MAPT
SCHEMBL3355530 0.75 NPY1R (0.36) LMNAELANEKDM4ESMN1; SMN2MAPT
SCHEMBL6099481 0.69 ALDH1A1 (0.40) LMNASMN1; SMN2MAPTALDH1A1MEN1
SCHEMBL13588384 0.69 CYP1A2 (0.32) LMNAELANEPTGDR2KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070219196-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219196-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES IL2, IL4, IFNG LMNA 4342/4885ELANE 1063/4885PTGDR2 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.